stockrow
Saturday 7 November 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −43.4%
- Total debt
- −15.7%
Quarter to June 2026, against a year earlier
25.16
3.29
+15.04%
Follow ANRO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.01%) | (41.80%) | (38.86%) | (49.17%) | |
| (36.77%) | (34.92%) | (33.16%) | (40.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(47.01%) | (37.58%) | (28.77%) | (36.20%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.99) | (1.80) | (1.91) | (1.61) | |
Free Cash Flow |
(53.80) | (51.79) | (62.86) | (68.84) | |
Capital Expenditures |
(0.53) | (0.02) | (0.56) | (0.56) | |
| Other line items | |||||
Cash ROIC |
(19.79%) | (14.94%) | (11.96%) | (14.29%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(29.77) | (26.88) | (32.21) | (39.04) | |
Operating CF/Net income |
0.86 | 0.82 | 0.84 | 0.81 | |
Depreciation/Fixed assets |
0.33 | 0.35 | 0.30 | 0.34 | |
Capex/Depreciation |
(0.79) | (0.04) | (0.82) | (0.81) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.97) | (1.79) | (1.89) | (1.59) | |
Capex per Share |
(0.02) | 0.00 | (0.02) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates